All In Biotech

Drug Trial Radar · NCT04776187

Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging

Safety Evaluation of Linear and Macrocyclic Gadolinium-Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging (Interventional Prospective Study) Clinical Trial Protocol

Last checked: Nov 19, 2026Latest source record: Mar 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

600

Planned (sponsor's estimate)

Start

Mar 1, 2021

Primary completion

Dec 31, 2021

Study completion Dec 31, 2021

Sponsor

Lead sponsor
The Central Hospital of Lishui CityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Jiangsu Hengrui Pharmaceutical Co., Ltd.
First posted
Mar 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety of linear and macrocyclic gadolinium-based contrast agents for patients with mild to moderate renal insufficiency. The study will compare the incidence of adverse events of gadodiamide and gadoteric Acid Meglumine Salt for patients with mild to moderate renal insufficiency undergoing enhanced magnetic resonance imaging.

Conditions

  • Nephrogenic Fibrosing Dermopathy

Interventions

  • GadodiamideDrug

    Gadodiamide Injection(OMNISCAN™)

  • Gadoteric Acid Meglumine SaltDrug

    Gadoteric Acid Meglumine Salt Injection(Jia Di Xian™)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of various adverse eventsTime frame: From the date of contrast injection to the incidence of adverse events, assessd up to 60 minutes
  2. The incidence of various adverse eventsTime frame: From the date of contrast injection to the incidence of adverse events, assessd up to 3 months
  3. The incidence of various adverse eventsTime frame: From the date of contrast injection to the incidence of adverse events, assessd up to 6 months
  4. The incidence of various adverse eventsTime frame: From the date of contrast injection to the incidence of adverse events, assessd up to 12 months
  5. The incidence of various adverse eventsTime frame: From the date of contrast injection to the incidence of adverse events, assessd up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lishui Central Hospital

    Lishui, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.